Cholinergic stimulation with pyridostigmine reduces the QTc interval in coronary artery disease
Braz. j. med. biol. res
; 35(6): 685-689, June 2002. ilus, tab
Article
en En
| LILACS
| ID: lil-309517
Biblioteca responsable:
BR1.1
ABSTRACT
Parasympathetic dysfunction is an independent risk factor in patients with coronary artery disease; thus, cholinergic stimulation is a potential therapeutic measure that may be protective by acting on ventricular repolarization. The purpose of the present study was to determine the effects of pyridostigmine bromide (PYR), a reversible anticholinesterase agent, on the electrocardiographic variables, particularly QTc interval, in patients with stable coronary artery disease. In a randomized double-blind crossover placebo-controlled study, simultaneous 12-lead electrocardiographic tracings were obtained at rest from 10 patients with exercise-induced myocardial ischemia before and 2 h after the oral administration of 45 mg PYR or placebo. PYR increased the RR intervals (pre 921 ± 27 ms vs post 1127 ± 37 ms; P<0.01) and, in contrast with placebo, decreased the QTc interval (pre 401 ± 3 ms vs post 382 ± 3 ms; P<0.01). No other electrocardiographic variables were modified (PR segment, QT interval, QT and QTc dispersions). Cholinergic stimulation with PYR caused bradycardia and reduced the QTc interval without important side effects in patients with coronary disease. These effects, if confirmed in studies over longer periods of administration, may suggest a cardioprotection by cholinergic stimulation with PYR
Texto completo:
1
Colección:
01-internacional
Base de datos:
LILACS
Asunto principal:
Bromuro de Piridostigmina
/
Inhibidores de la Colinesterasa
/
Enfermedad Coronaria
Tipo de estudio:
Clinical_trials
/
Risk_factors_studies
Límite:
Humans
Idioma:
En
Revista:
Braz. j. med. biol. res
Asunto de la revista:
BIOLOGIA
/
MEDICINA
Año:
2002
Tipo del documento:
Article
/
Project document
País de afiliación:
Brasil
Pais de publicación:
Brasil